David Oser

David Oser is a partner in Homburger's Corporate / M&A team and focuses on public and private M&A transactions, with a focus on private equity. He also advises on corporate governance, executive compensation and ESG matters. He co-leads the firm’s ESG reporting practice.

• Advised BeOne Medicines Ltd. on the redomestication of its public holding company to Switzerland from the Cayman Islands (2025);

• Advised Bunge Global SA in its combination with Viterra (2025);

• Advised Roche Holding AG  in the exchange of its Genussscheine for participation certificates (2025);

• Advised Lakera AI AG on its sale to Check Point (2025);

• Advised IonQ, Inc. on its acquisition of id Quantique SA (2025).

• Capital markets: Equity
• M&A
• Private equity

• Consumer goods and services
• Healthcare
• Oil and gas
• Pharmaceutical and life sciences
• Technology and telecommunications

• Dr. iur, University of Basel, 2007
• LL.M., Columbia Law School, 2000
• lic. iur., University of Basel, 1995

• Swiss-American Chamber of Commerce, Member of the Legal Chapter
• Zurich Bar Association

• New York
• Switzerland